FDA approves daraxonrasib, the first RAS inhibitor cleared for pancreatic cancer

The United States Food and Drug Administration approved the drug daraxonrasib as a treatment for metastatic pancreatic cancer. It is the first RAS inhibitor approved for that disease. Approval followed a study in which the drug nearly doubled the survival rate for patients compared with chemotherapy. The report names the drug, the cancer, and the comparison.

Metastatic disease means the cancer has spread. A RAS inhibitor is the drug class named. Being first in that class for this disease is the regulatory distinction. The report does not give the survival times in months. It states the near-doubling relative to chemotherapy.

Chemotherapy is the comparison treatment in the study. Nearly doubled is the effect size as summarized, not a promise for every patient. The report does not list side effects. It does not state a price.

Separately, neurosurgeons in London performed what was reported as the first AI-assisted brain surgery at the National Hospital for Neurology and Neurosurgery. The patient was 48 and had been diagnosed with a brain tumor in 2024. That surgery is a different medical first from the drug approval. It is included here only as the other major treatment report of the day, not as part of the daraxonrasib trial.

The drug news does not say daraxonrasib cures pancreatic cancer. It says regulators approved it and that a previous study showed a near doubling of survival compared with chemotherapy. The surgery news does not give an outcome for the 48-year-old patient beyond the fact of the operation. Each claim stays inside its report.

The confirmed health facts are the approval of daraxonrasib for metastatic pancreatic cancer, its status as the first RAS inhibitor approved for the disease, the study comparison with chemotherapy, and a first AI-assisted brain operation in London on a 48-year-old patient diagnosed in 2024. Side effects and a price for the drug are not stated. The surgery report does not give the patient's outcome beyond the operation itself.